AgomAb Therapeutics SA
52.0 FTEAgomAb Therapeutics reported total assets of €251.3m at the end of the 2025 financial year (annual accounts filed with the NBB on 23 Jun 2026), with 52 full-time equivalents.
By total assets for 2025, AgomAb Therapeutics is the largest of the 843 companies in its sector (NACE 7120) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of AgomAb Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +152 % Total assets +148 % Headcount (avg FTE) +415 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
AgomAb Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jun 2026
- Year ended 31 Dec 2024filed on 03 Jun 2025
- Year ended 31 Dec 2023filed on 27 Jun 2024
- Year ended 31 Dec 2022filed on 03 Jul 2023
- Year ended 31 Dec 2021filed on 29 Jun 2022
AgomAb Therapeutics's financial analysis
- Solvency97.1%sector median: 53.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of AgomAb Therapeutics
AgomAb Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0674.527.310
- VAT number
- BE0674527310
- Peppol
- Registered · 0208:0674527310 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 13 Apr 2017
- Registered office
- 2600 Antwerp
- Size
- Medium · 52.0 FTE
- Latest accounts
- 2025 · filed on 23 Jun 2026
- Activity
- Other technical testing and analysis activities (NACE 71209)
AgomAb Therapeutics (SA) has been based in Antwerp since 2017, active in: other technical testing and analysis activities. For 2025, it reports a net loss of €9.62m and equity of €244.1m; its revenue is not published. With 52.0 full-time equivalents, it is a medium-sized enterprise by headcount. Its solvency stands at 97.1%, above the median of its sector (53.2%).
Guide: Checking a Belgian supplier invoice: numbers and IBAN →
Companies similar to AgomAb Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- MDxHealth Research and experimental development on natural sciences and engineering Herstal · balance sheet €159.3m
- Devgen Research and experimental development on natural sciences and engineering Ghent · balance sheet €130.9m
- Ablynx Research and experimental development on natural sciences and engineering Ghent · balance sheet €417.3m
- Ncardia Holding Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €108.4m
- Omega Pharma Innovation & Development Research and experimental development on natural sciences and engineering Ghent · balance sheet €246.6m
- Ardena Holding Research and experimental development on natural sciences and engineering Ghent · balance sheet €87.1m
- Confo Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €37.8m
- iTeos Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet €46.3m
Frequently asked questions about AgomAb Therapeutics
What is the revenue of AgomAb Therapeutics?
AgomAb Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of AgomAb Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0674527310 for AgomAb Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0674.527.310.
Where is the registered office of AgomAb Therapeutics?
According to the CBE register, the registered office of AgomAb Therapeutics is in 2600 Antwerp.
What is the equity of AgomAb Therapeutics?
At the close of the 2025 financial year, the equity of AgomAb Therapeutics amounts to 244,064,213 €, a solvency of 97.1% of total assets.
How many people work at AgomAb Therapeutics?
52.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages AgomAb Therapeutics?
The register lists 7 active mandates at AgomAb Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is AgomAb Therapeutics within its sector?
By total assets for 2025, AgomAb Therapeutics is the largest of the 843 companies in its sector (NACE 7120) in Belgium that filed accounts for that financial year.
The full file of AgomAb Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →